3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
63
Carcinoma, Intraductal, Noninfiltrating
8
Breast Carcinoma In Situ
6
Neoplasms
4
Breast Neoplasms, Male
3
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Infertility
2
Endometrial Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Precancerous Conditions
1
Polycystic Ovary Syndrome
1
Pinealoma
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Medulloblastoma
1
Inflammatory Breast Neoplasms
1
Hypogonadism
1
Hyperglycemia
1
Hot Flashes
1
Interventions
Fulvestrant
5
serabelisib
2
sapanisertib
2
ribociclib
2
palbociclib
2
Paclitaxel
2
Letrozole
2
Irinotecan
2
Gemcitabine
2
Carboplatin
2
Alpelisib
2
venetoclax
1
tivozanib
1
tipifarnib
1
sotorasib
1
pembrolizumab
1
olaparib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
ceralasertib
1
cemiplimab
1
capivasertib
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled